Definitive three-dimensional high-dose-rate brachytherapy for inoperable endometrial cancer.
CONCLUSIONS: Although some limitations of our analysis (relatively few number of patients recruited, retrospective evaluation, and consequent suboptimal patient selection), it confirms effectiveness and safety of definitive HDR-BT for medically inoperable stage I-III endometrial cancer. The best LC was obtained in stage I low-risk histology.
PMID: 28533799 [PubMed - in process]
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
More News: Adenocarcinoma | Bleeding | Brachytherapy | Cancer | Cancer & Oncology | Carcinoma | CT Scan | Endometrial Biopsy | Endometrial Cancer | External Beam Therapy | Toxicology